MET amplification increases the metastatic spread of EGFR-mutated NSCLC
Published online: September 11, 2018 – DOI: https://doi.org/10.1016/j.lungcan.2018.09.008 Background Five to 20% of metastatic EGFR-mutated non-small cell lung cancers (NSCLC) develop acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI) through MET amplification. The effects of MET amplification on tumor and patient phenotype remain unknown. Methods We investigated,in vitro and in vivo, the impact of MET Read more about MET amplification increases the metastatic spread of EGFR-mutated NSCLC[…]